Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. - Wikidata - awgldk - TriplyDB

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

http://www.wikidata.org/entity/Q37391070

about

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.Rituximab maintenance in follicular lymphoma patients Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy The immune microenvironment of myeloma Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report.SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.Considerations in the initial management of follicular lymphoma.Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies.A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders Progress in the development of a therapeutic vaccine for breast cancer.The late adverse events of rituximab therapy--rare but there!Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.Rituximab: a review of dermatological applications.Biology and treatment of follicular lymphoma.New antibody drug treatments for lymphoma.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Follicular lymphoma: current management and future directions.Cost-effectiveness of rituximab in follicular lymphoma.

P2860

Q27000310-62C9FE99-83DC-4F1F-9188-CF82C454168F Q27025272-7149CB67-09BF-4821-B5AD-625020B1FC0E Q28073262-90526702-E1A4-4D42-AAA7-72B43605BDE1 Q30370665-3E0C0566-0C09-436E-909C-293334BFA2AA Q30500238-204E735A-2F71-408F-8C47-4FCCECA5BBEF Q33971785-FE8B7521-D296-4C6B-AB69-B3117B7F1478 Q33990849-51D840D7-886E-4B19-ACD4-1451B28C90D2 Q34065271-726A40FC-08B9-4992-8063-B119F3E9F5C6 Q34488720-1C34EBEB-EB8D-4059-BF7C-BDCE3765B12B Q34815753-0637DB5C-F58E-4C51-B2C5-0E9FD2A35A15 Q34854149-BF76448D-E7B9-4FD2-99B0-5FC486719E50 Q35113379-CA0C9B55-65C7-47F9-9356-CA428ADE2383 Q35237511-D343D858-ACC3-49A3-9DB3-2F58954AA147 Q35583773-A7F4521A-3D4A-4F5B-9B15-70F9DFCB1F59 Q35603152-32D0E80D-EA06-4F9A-9B74-DD642E82AE23 Q35800846-F1C6D00B-3DA1-4A0C-8091-9543B21D7E7A Q36036378-7FF60F52-4989-4C4C-ABE5-2FCCFC4D21E8 Q36216264-6FCA268C-FD97-45C1-9078-10D984D3429A Q36330730-4E0388D4-A2D9-4754-BA27-D49D53D7B18D Q36400279-5F822B25-E128-4B23-8DB9-E8746707ACB0 Q36612574-23503514-90F9-4B86-A8E6-102B36D1BE01 Q36724776-38D9CCA7-6D72-4C2C-8F05-F70A21683215 Q36978418-26A826C0-F33D-4D0C-A4C6-44517EEE398F Q37265471-E6A6CA26-4B22-4C7D-A849-719A8299F212 Q37355578-51C509B5-BA3A-4520-9779-9231DB427707 Q37462485-9E22DFA5-8624-467F-AC46-DA56014FD9E8 Q37773249-108E8419-60A4-4B4E-91FA-C4CD361F60F0 Q37781697-BF6A7B02-8E63-4C22-9895-0FB3C8394E16 Q37810118-4111C0CE-98F5-4840-84BF-BB1AF8D90C34 Q37852003-F0C60E81-42C7-4553-B83B-E1281DABA37D Q37854714-5A473D3F-C72A-4AC2-90F9-95AC811FDD62 Q37862618-0BF0DE5A-AF01-4314-B4EB-2605C317D764 Q37875060-04B41A94-3A6F-4C53-996E-3F8FBA3693ED Q37919869-218B0148-4975-4D43-9715-219C6C44497C Q37930456-30B5E35E-F00E-4482-8393-117057C882BA Q37940552-B25855F6-6791-4721-8B56-57150E551EFE Q37948748-0EEB2111-1265-44E2-A25A-A42170ED3DBB Q37975154-07A34FFE-8409-47BD-8976-D8ED7457A7D6 Q38019789-15D81B5B-BBFA-4FB8-AB8D-67CEB9E3293A Q38058840-227B0EA9-0BF6-40D9-B928-0DB9D05343A2

P2860

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

http://www.wikidata.org/entity/Q37391070

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

type

label

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

prefLabel

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

P1433

Q37391070-9848D6DE-4011-4D67-B9DB-60D210FA789F

P1476

Q37391070-331AB0C0-4C47-4EF4-89FC-CCD2396E8999

P2093

Q37391070-0EB38762-AFB9-4073-BE60-DEF10C66C45A

Q37391070-1EF4D225-A984-4B8D-8056-2CE06A5EA9BC

Q37391070-61C994ED-4909-463E-8DF9-64B579B87E56

Q37391070-8AA76F5C-71AF-4455-A323-AFE8DA57C703

Q37391070-A3DFE614-E7B8-4689-8329-7275E3011954

Q37391070-B15D7DA0-0EC4-4A8C-8445-E142ACD88733

Q37391070-EFBFA4B9-869D-4ADA-A4A1-6169747956B8

P2860

Q37391070-19D264E6-8B87-4C68-B032-23039F9DE589

Q37391070-29117F9A-6793-4706-9BB9-DA70BB46777E

Q37391070-2A06B3AE-EE54-4550-94FE-7E7307CCA385

Q37391070-2BD51200-B876-47D6-AF9C-666252A0B664

Q37391070-34C545AE-C728-40D1-82BF-25B5C5C8D633

Q37391070-500FD356-1F5D-451D-9B34-E7971E7A374A

Q37391070-56B49B7B-067F-44C3-940E-3158511B0268

Q37391070-68D41FD2-5F5C-492F-A197-E5D0AB8838FA

Q37391070-77C87B18-CF60-4A32-B751-41195F760459

Q37391070-8955A48A-2552-47DD-A44E-A628030D3E41

P304

Q37391070-FB44353B-7AE7-4E66-B38A-2989533E2C30

P31

Q37391070-313F5F08-18D4-4F99-BC4E-353F2CB5719A

Q37391070-f68b5dcc-2c80-43dc-b013-598b78bb2f1c

P356

Q37391070-EDB66609-1A9F-49BC-A3E0-E0E9212E91D1

P407

Q37391070-7C30758E-5F47-4D69-B09D-01939CA150DD

P433

Q37391070-471B5FD9-22D4-4C42-8473-CC63FDC4A2FC

P478

Q37391070-E25358CE-5D35-43EE-8971-4AE6D95488F3

P50

Q37391070-C4928703-EAA2-4B1B-991C-FD373BBB1873

P577

Q37391070-F76074E8-4D65-4D36-8ED8-56E094BDA684

P5875

Q37391070-04B1C663-38C4-49DE-830F-93A5A4D2B28D

P698

Q37391070-BF79DCCB-F5C7-4BF3-9DC9-4AF78F25CD99

P921

Q37391070-791918E6-6883-4805-8BDF-BC9E4D380284

Q37391070-7FFEF77B-5579-4D01-9669-EC153C84E0AB

P356

P1433

Journal of the National Cancer Institute

P1476

Rituximab maintenance for the ...... analysis of randomized trials.

@en

P2093

Amos Cohen

http://www.w3.org/2001/XMLSchema#string

Anat Gafter-Gvili

http://www.w3.org/2001/XMLSchema#string

Liat Vidal

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Michele Ghielmini

http://www.w3.org/2001/XMLSchema#string

Ofer Shpilberg

http://www.w3.org/2001/XMLSchema#string

Shu-Fang Hsu Schmitz

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Measuring inconsistency in meta-analyses

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Meta-analysis in clinical trials

Practical methods for incorporating summary time-to-event data into meta-analysis

Systematic reviewers neglect bias that results from trials stopped early for benefit.

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Randomized trials stopped early for benefit: a systematic review.

P304

248-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJN478

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Leonard Leibovici

P577

2009-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24002539

http://www.w3.org/2001/XMLSchema#string

P698

19211444

http://www.w3.org/2001/XMLSchema#string

P921